TG Therapeutics (TGTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Edward White from H.C. Wainwright reiterated a Buy rating on the stock and has a $55.00 price target.
Edward White has given his Buy rating due to a combination of factors including the strong financial performance and promising future outlook of TG Therapeutics. The company’s 4Q24 results exceeded expectations, with GAAP EPS and non-GAAP EPS surpassing both the firm’s estimates and consensus. This positive performance was driven by robust sales of Briumvi, TG Therapeutics’ novel treatment for relapsing forms of multiple sclerosis, which saw a significant year-over-year increase in revenue.
Furthermore, the company has provided optimistic guidance for 2025, projecting substantial growth in both revenue and earnings. TG Therapeutics has also demonstrated effective cash flow management and maintains a solid cash position, which supports its operational and strategic initiatives. The expansion of its field team and record enrollments into its hub further underscore the company’s growth potential. These factors collectively underpin Edward White’s Buy rating for TG Therapeutics’ stock.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TGTX in relation to earlier this year.
Questions or Comments about the article? Write to editor@tipranks.com